Rai Yoshiaki, Sagara Yoshiaki, Sagara Yoshiatsu, Ooi Yasuyo
Dept. of Breast Surgery, Sagara Hospital.
Gan To Kagaku Ryoho. 2004 Mar;31(3):443-7.
Case 1 is a 38-year-old woman with a 6 cm tumor in her right breast. After incisional biopsy she received 2 cycles of CMF and tamoxifen in order to effect down staging. The tumor markedly decreased in size. She next underwent breast conserving surgery. Histopathologically, malignant cells completely disappeared (pCR). Case 2 is a 34-year-old woman with a 5.5 cm tumor in her left breast. After incisional biopsy she received the same regimen as in case 1. The tumor diminished significantly in size, and she underwent breast conserving surgery. Histopathologically, only a few fragments of degenerated tumor cells remained. Case 1 was hormone receptor positive, while case 2 was negative. The remarkable responsiveness (pCR and near pCR) to 2 cycles of CMF combined with tamoxifen was interesting. From these results we conclude that the CMF regimen is an useful neoadjuvant chemotherapy alternative to avoid alopecia and GI tract side effects.
病例1是一位38岁女性，右乳有一个6厘米的肿瘤。在进行切开活检后，她接受了2个周期的CMF方案和他莫昔芬治疗，以实现降期。肿瘤大小明显减小。接下来她接受了保乳手术。组织病理学检查显示，恶性细胞完全消失（pCR）。病例2是一位34岁女性，左乳有一个5.5厘米的肿瘤。在进行切开活检后，她接受了与病例1相同的治疗方案。肿瘤大小显著减小，她接受了保乳手术。组织病理学检查显示，仅残留少数退变的肿瘤细胞碎片。病例1激素受体阳性，而病例2为阴性。2个周期的CMF方案联合他莫昔芬所产生的显著反应（pCR和接近pCR）很有意思。从这些结果我们得出结论，CMF方案是一种有用的新辅助化疗选择，可避免脱发和胃肠道副作用。
